Patents Assigned to Galderma Laboratories, Inc.
-
Patent number: 8426410Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.Type: GrantFiled: August 21, 2009Date of Patent: April 23, 2013Assignee: Galderma Laboratories, Inc.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin
-
Patent number: 8410102Abstract: Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one ?-adrenergic receptor agonist and a pharmaceutically acceptable carrier.Type: GrantFiled: March 25, 2011Date of Patent: April 2, 2013Assignee: Galderma Laboratories Inc.Inventors: Michael Graeber, Christian Loesche, Philip Freidenreich, Jack A. Dejovin, Isabelle Jean Dejovin, Yin-Sang Liu, Matthew James Leoni
-
Publication number: 20120277241Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.Type: ApplicationFiled: July 10, 2012Publication date: November 1, 2012Applicant: GALDERMA LABORATORIES, INC.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin
-
Publication number: 20120220555Abstract: A method for simultaneously treating ocular rosacea and acne rosacea in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat ocular rosacea and acne rosacea but has substantially no antibiotic activity.Type: ApplicationFiled: May 7, 2012Publication date: August 30, 2012Applicant: GALDERMA LABORATORIES, INC.Inventor: Robert A. Ashley
-
Patent number: 8231885Abstract: Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an ?-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours.Type: GrantFiled: August 20, 2009Date of Patent: July 31, 2012Assignee: Galderma Laboratories Inc.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin
-
Patent number: 8211874Abstract: The present invention is a method for inhibiting undesirable thrombin generation in a mammal in need thereof. The method comprises administering to the mammal an effective amount of a non-antibacterial tetracycline formulation.Type: GrantFiled: June 1, 2006Date of Patent: July 3, 2012Assignee: Galderma Laboratories Inc.Inventors: Klaus Theobald, Jerrold H. Levy
-
Patent number: 8192749Abstract: A method for simultaneously treating ocular rosacea and acne rosacea in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat ocular rosacea and acne rosacea but has substantially no antibiotic activity.Type: GrantFiled: November 16, 2005Date of Patent: June 5, 2012Assignee: Galderma Laboratories Inc.Inventor: Robert A. Ashley
-
Publication number: 20120108552Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.Type: ApplicationFiled: October 20, 2011Publication date: May 3, 2012Applicant: GALDERMA LABORATORIES, INC.Inventor: Robert A. Ashley
-
Publication number: 20110288096Abstract: Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one ?-adrenergic receptor agonist and a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 25, 2011Publication date: November 24, 2011Applicant: GALDERMA LABORATORIES INC.Inventors: Michael GRAEBER, Christian LOESCHE, Philip FREIDENREICH, Jack A. DEJOVIN, Isabelle Jean DEJOVIN, Yin-Sang LIU, Matthew J. LEONI
-
Publication number: 20110286945Abstract: Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an ?2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours.Type: ApplicationFiled: August 2, 2011Publication date: November 24, 2011Applicant: GALDERMA LABORATORIES INC.Inventors: Jack DeJovin, Isabelle Jean DeJovin
-
Patent number: 8052983Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.Type: GrantFiled: October 22, 2007Date of Patent: November 8, 2011Assignee: Galderma Laboratories, Inc.Inventor: Robert A. Ashley
-
Publication number: 20110262542Abstract: A composition is provided for delivering a tetracycline compound to a mammal. The composition includes an antibiotic tetracycline compound and a controlled-release agent having at least one controlled-release agent. The tetracycline compound is associated with the controlled-release matrix to provide a release profile whereby the mammal is treated substantially without antibiotic activity. Methods for treating a mammal with a tetracycline compound and a dosage unit are also provided utilizing the controlled-release tetracycline composition.Type: ApplicationFiled: July 6, 2011Publication date: October 27, 2011Applicant: GALDERMA LABORATORIES INC.Inventor: Robert A. Ashley
-
Publication number: 20110224216Abstract: A method of treating or preventing acute erythema in a human in need thereof by topical administration of an effective amount of an alpha adrenergic receptor agonist or pharmaceutically acceptable salt thereof is claimed. The preferred alpha adrenergic receptor agonist is brimonidine. A method of preventing secondary inflammation caused by acute erythema by topical administration of an effective amount of an alpha adrenergic receptor agonist or a pharmaceutically acceptable salt thereof is also claimed.Type: ApplicationFiled: October 19, 2010Publication date: September 15, 2011Applicant: GALDERMA LABORATORIES INC.Inventors: Philippe Andres, Christian Loesche, Michael Graeber
-
Publication number: 20110224215Abstract: The invention relates to a method of reducing post-surgical bleeding and/or bruising in a patient scheduled to be subjected to a surgical procedure and a patient that was subjected to a surgical procedure. The method involves topically applying to the area and the surrounding area of skin of the patient where the surgical procedure will be or was performed, a pharmaceutical composition comprising an effective amount of brimonidine or a pharmaceutically acceptable salt thereof, prior to performing the surgical procedure and/or following the surgical procedure.Type: ApplicationFiled: December 17, 2008Publication date: September 15, 2011Applicant: GALDERMA LABORATORIES, INC.Inventor: Jack A. DeJovin
-
Patent number: 7838563Abstract: Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an ?-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours.Type: GrantFiled: June 8, 2006Date of Patent: November 23, 2010Assignee: Galderma Laboratories Inc.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin, Christopher Powala
-
Publication number: 20100227867Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.Type: ApplicationFiled: August 21, 2009Publication date: September 9, 2010Applicant: Galderma Laboratories Inc.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin, Thomas M. Rossi
-
Publication number: 20100130502Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.Type: ApplicationFiled: November 18, 2009Publication date: May 27, 2010Applicant: GALDERMA LABORATORIES, INC.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin
-
Publication number: 20100021402Abstract: Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an ?-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours.Type: ApplicationFiled: August 20, 2009Publication date: January 28, 2010Applicant: Galderma Laboratories Inc.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin, Christopher Powala
-
Patent number: 7456158Abstract: The present invention provides new chemically modified 4-dedimethylaminotetracycline compounds that can be substituted with aryl, alkenyl, or alkynyl groups. The 7, 8, and/or 9 positions and methods for preparing such compounds. Other tetracycline compounds include the 4-dedimethylaminotetracycline derivatives with an oxime group, NH-Alkyl, or N—NH-Alkyl group substituted at the C4 position as well as C2 Mannich derivatives. The present invention also provides a method of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the new chemically modified tetracycline compounds.Type: GrantFiled: January 5, 2005Date of Patent: November 25, 2008Assignee: Galderma Laboratories, Inc.Inventors: Robert Ashley, Joseph J. Hlavka
-
Patent number: 7439241Abstract: In methods, compounds, and topical formulations for treatment of rosacea incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat rosacea and its symptoms.Type: GrantFiled: May 25, 2004Date of Patent: October 21, 2008Assignee: Galderma Laboratories, Inc.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin